Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
- Rheumatoid Arthritis
- La Madeleine
- Le Coudray
- Le Kremlin-Bicêtre
- Le Puy-en-Velay
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).
Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year
- Participants at least 18 years old
- Participants with moderate to severe RA not previously treated with TCZ (Intravenous [IV] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)
- Participants taking part in a clinical trial on RA at the time of inclusion
- Participants with a contra-indication to TCZ SC therapy
For the latest version of this information please go to www.forpatients.roche.com